44 results about "Lactobacillus johnsonii" patented technology

The invention discloses combined probiotics for improving sarcopenia as well as a preparation method and application of the combined probiotics, and belongs to the field of probiotics. The invention relates to a combined probiotic for improving sarcopenia. The combined probiotic comprises a lactobacillus reuteri body, a lactobacillus johnsonii body, a lactobacillus fermentum body and a bifidobacterium adolescentis body. The combined probiotics disclosed by the invention can be used for remarkably improving the overall symptoms of sarcopenia model mice, including inhibiting weight loss, constipation symptoms and colonic mucosa destruction, prolonging load swimming time, improving muscle endurance, improving skeletal muscle atrophy, improving the expression of I-type slow muscle fiber protein MyHC I and promoting slow muscle fiber repair, and has the effects of preventing and treating sarcopenia. The invention discloses a probiotic intervention method for treating sarcopenia, which comprises the following steps of: preparing probiotics for treating sarcopenia, reducing the content of inflammatory cytokines in muscular tissues, increasing the content of hepatic glycogen, improving systematic metabolism of mice with sarcopenia and damaged serum markers, including lactic acid, lactic dehydrogenase, creatine kinase, creatinine, alanine transaminase ALT and aspartate transaminase AST, providing a new scheme for probiotic intervention for sarcopenia, and being used for preparing related functional products or intervention means.

This invention proposes a molecular marker for *Lactobacillus japonicus*, which was deposited on February 7, 2023, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 26505. The molecular marker comprises a nucleotide sequence selected from one of the following: (1) the nucleotide sequence shown in SEQ ID NO: 24; (2) a nucleotide sequence having at least 97%, 98%, 99%, or higher homology to the nucleotide sequence shown in SEQ ID NO: 24; or (3) a nucleotide sequence having one or more nucleotide substitutions, deletions, or insertions in the nucleotide sequence shown in SEQ ID NO: 24. Using the molecular marker of this invention, not only can the target *Lactobacillus japonicus* be screened quickly and easily, but it can also highly specifically identify the target *Lactobacillus japonicus*, eliminating interference from other strains.

The method includes the steps of providing a plant protein substrate and fermenting the plant protein substrate with a starter culture containing *Lactobacillus johnsonii*. The invention also relates to plant-based products from such fermentation and *Lactobacillus johnsonii* strains suitable for use in the invention. The invention further relates to peptides that impart and / or enhance rich flavors, methods for preparing such peptides, compositions containing such peptides, and the use of such peptides as flavoring agents.

The application discloses a lactobacillus johnsonii OD-5 and application and products thereof, and belongs to the technical field of microorganisms. A technical problem to be solved by the application is to provide a lactobacillus johnsonii capable of treating kidney stones. A technical solution is a lactobacillus johnsonii OD-5 with a preservation number of CGMCC No. 38426. The lactobacillus johnsonii can reduce urine oxalic acid and regulate urine calcium, effectively correct abnormal urine biochemical conditions promoting stone formation, reduce related kidney function damage, and inhibit formation and deposition of calcium oxalate crystals in the kidney at a histopathological level, thereby significantly reducing the stone incidence. The application provides a solid theoretical basis for development of products taking the lactobacillus johnsonii OD-5 as a core component and used for preventing kidney stones and improving stone kidney damage.

The present application relates to lactic acid bacteria with blood sugar lowering function and application thereof, and particularly provides a group of lactic acid bacteria with high safety, which can play an important role in regulating intestinal microecological balance of human body and has blood sugar lowering effect.The lactic acid bacteria is named as Lactobacillus johnsonii 4437-4AT, the strain number is 4437-4AT, and was preserved in Guangdong Microbial Culture Collection Center on January 20, 2026, the preservation address is: No. 59 Building, 5th Floor, Guangzhou Xianlie Middle Road 100 Courtyard, the preservation number is: GDMCC NO: 67710.

The invention discloses a broiler feed additive containing chlorella and application of the broiler feed additive. The additive contains chlorella; the feed also contains one or more of lactobacillus johnsonii, enterococcus faecalis, saccharomyces cerevisiae and bacillus amyloliquefaciens. By adding the additive disclosed by the invention into daily ration, the intestinal tissue form can be improved by regulating antioxidant and immune functions, so that the growth performance of the broiler chicken can be remarkably improved. In the additive, lactobacillus johnsonii BS15 and enterococcus faecalis YP-2 are combined for use, and saccharomyces cerevisiae WHY-7 and bacillus amyloliquefaciens TL are combined for use, so that the average weight of the broiler chicken is increased, the spleen index after LPS stimulation is reduced, and synergistic interaction is achieved.

The invention discloses a lactic acid bacteria composition, lactic acid bacteria fermentation liquor, a lactic acid bacteria agent, fermented milk and a preparation method and application thereof, and belongs to the technical field of microorganisms. The lactobacillus composition disclosed by the invention is prepared from lactobacillus johnsonii S2L, lactobacillus reuteri S5L and lactobacillus mucous membrane mucus S16L; the preservation number of the lactobacillus johnsonii S2L is GDMCC No: 66569; the preservation number of the lactobacillus reuteri S5L is GDMCC No: 66558; the preservation number of the lactobacillus mucous membrane S16L is GDMCC No: 66559. The strains in the lactic acid bacteria composition have excellent probiotic characteristics, do not have virulence factors, are fermented in the milk replacer, are short in fermentation time, can improve the protein hydrolysis degree of the milk replacer, reduce the incidence rate of lamb diarrhea and optimize the intestinal microflora, and have positive effects on improving the feed intake of lambs.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus johnsonii with a function of resisting multiple drug-resistant bacterium biological membranes and anti-inflammatory activity and application of the lactobacillus johnsonii. The lactobacillus johnsonii A25041 provided by the invention has strong inhibition and anti-biofilm activity on multi-drug-resistant gram-negative bacteria (including escherichia coli, pseudomonas aeruginosa and acinetobacter baumannii) and methicillin-resistant staphylococcus aureus, and the lactobacillus johnsonii A25041 has good acid-base tolerance and gastrointestinal fluid tolerance, so that the lactobacillus johnsonii A25041 can be used for preparing medicines for preventing and treating various diseases. The composition shows excellent anti-inflammatory activity and oxidation resistance, does not have hemolysis capacity, is good in safety, has natural drug resistance to gentamicin, tetracycline, ciprofloxacin, lincomycin and compound sulfamethoxazole, can be used together with antibiotics at the same time or in sequence, maintains intestinal microecological balance and relieves antibiotic burden while exerting the sterilization effect of the antibiotics, and has a good application prospect. The method can be widely applied to functional food development, and has important application value in the field of biological medicine and daily chemical products.

The present application relates to a lactobacillus johnsonii producing a novel class III bacteriocin, an engineered bacterium and application thereof, and belongs to the technical field of microorganisms. Lactobacillus johnsonii The JLJ071 strain of the lactobacillus johnsonii is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC No.34541. The bacteriocin amino acid sequence is shown in Seq ID No.1. The expressed novel class III bacteriocin has good bactericidal activity on listeria monocytogenes and salmonella pullorum, and has good characteristics such as acid resistance, high temperature resistance and protease resistance, and has a good application prospect in feed additives.

This invention relates to a lactobacillus composition for alleviating atopic dermatitis. This lactobacillus composition comprises at least one of *Lactobacillus johnsonii* strain GKJ2 and *Lactobacillus plantarum* strain GKK1. When administered to subjects suffering from atopic dermatitis for a continuous period, it can regulate Th1, Th2, Treg, and Th17 cellular immunity, alter the intestinal flora, and increase the concentration of short-chain fatty acids in the intestine, thereby alleviating atopic dermatitis. Therefore, this lactobacillus composition can be used as an active ingredient in the preparation of various compositions for alleviating atopic dermatitis.

The present disclosure provides use of a probiotic composition comprising active ingredients including Lactobacillus johnsonii, Lactobacillus gasseri, Lactobacillus crispatus, and Lactobacillus jensenii in the preparation of a microbial formulation, wherein the microbial formulation is used for: improving the therapeutic effect of an additional drug for treating bacterial vaginosis in the treatment of bacterial vaginosis; improving the prognosis of bacterial vaginosis treated with an additional drug for treating bacterial vaginosis; treating, preventing, mitigating, and / or controlling the recurrence of bacterial vaginosis in a subject; treating, preventing, mitigating, and / or controlling atrophic vaginitis in a subject; improving the Nugent score of a subject; or ameliorating vaginal dryness in a subject.

The invention discloses application of lactobacillus johnsonii or extracellular vesicles derived from the lactobacillus johnsonii in preparation of medicines for treating and / or preventing adult degenerative scoliosis. Experiments prove that the extracellular vesicles derived from lactobacillus johnsonii can promote synthesis of extracellular matrix (ECM) of nucleus pulposus cells derived from adult degenerative scoliosis (ADS), inhibit ECM degradation and effectively reverse nucleus pulposus ECM metabolism abnormality in the ADS progress process, and prompt that the extracellular vesicles can improve the ADS disease progress by regulating nucleus pulposus cell ECM metabolism.

The invention relates to the field of biological medicine, and discloses a composition targeting a lactobacillus johnsonii-tryptophan metabolic axis and application of the composition. The composition comprises a traditional Chinese medicine extract and lactobacillus johnsonii, the traditional Chinese medicine extract is prepared from radix bupleuri, radix paeoniae alba, fructus aurantii immaturus and honey-fried licorice root. Traditional Chinese medicine extracts of radix bupleuri, radix paeoniae alba, fructus aurantii immaturus and honey-fried licorice root are compounded with lactobacillus johnsonii according to a specific proportion, tryptophan is promoted to be converted into 5-hydroxytryptamine, kynurenine is inhibited from being generated, depression-like behaviors are effectively relieved, the traditional Chinese medicine composition can cooperate with anticancer drugs to remarkably inhibit cancer cell growth, meanwhile, the intestinal barrier function can be improved, the intestinal immunity can be improved, and the curative effect is good. The invention provides a high-safety synergistic treatment scheme with triple effects of tumor inhibition, depression resistance and intestinal tract improvement for patients with liver cancer and depression.

The invention discloses a method for regulating and controlling growth and metabolism of probiotics through low-intensity pulsed ultrasound and application of the method. The method comprises the steps that S1, a standardized co-culture system is obtained; s2, collecting co-culture flora density data and co-culture metabolite concentration data; s3, generating an optimal irradiation parameter record; s4, obtaining a steady-state co-culture product; s5, preparing a probiotic preparation containing lactobacillus johnsonii according to co-culture evaluation data, namely lactobacillus johnsonii which is subjected to low-intensity pulse ultrasonic irradiation and is suitable for growth and active in metabolism; s6, giving a probiotic preparation to the animal model, and meanwhile, applying low-intensity pulse ultrasonic irradiation corresponding to the optimal irradiation parameter record to the body surface positioning area of the animal intestinal tract to form an in-vivo joint regulation process; and S7, generating in-vivo regulation and control effect evaluation data. The low-intensity pulse ultrasonic technology is used, and side effects possibly caused by chemical drugs, gene modification and the like are avoided.

The invention belongs to the technical field of microbial fermentation engineering, and particularly relates to a method for increasing the yield of extracellular vesicles of lactobacillus bacteria. The method comprises the following steps: adding galactooligosaccharide into a lactobacillus selective culture medium, inoculating lactobacillus bacteria, and culturing; separating and purifying the cultured bacterial liquid to obtain extracellular vesicles; wherein the concentration of the galactooligosaccharide in the lactobacillus selective culture medium is 30 g / L-50 g / L. According to the invention, galactooligosaccharide is added in the culture of lactobacillus johnsonii, so that the production of extracellular vesicles of lactobacillus johnsonii can be effectively improved. The method can be used for industrial mass production of the lactobacillus johnsonii extracellular vesicles, and has important value in the field of production of the lactobacillus johnsonii extracellular vesicles.

The invention provides application of lactobacillus johnsonii YH1136 inactivated thalli in preparation of products for relieving depression, anxiety and sleep disorders, and relates to the technical field of microorganisms. The inactivated thallus is obtained by carrying out heat treatment on live thallus of lactobacillus johnsonii YH1136 with the preservation number of CCTCC NO: M 20221116 at 60 to 68 DEG C for 30 to 90 minutes. Animal experiments show that the inactivated thallus can significantly improve depression-like behaviors, anxiety-like behaviors and sleep disorders of CUMS model mice, and the effect of the inactivated thallus is equivalent to that of viable bacteria and positive drug fluoxetine, and is significantly superior to that of 100 DEG C traditional high-temperature inactivated thallus. The action mechanism is related to inhibition of HPA hyperfunction and up-regulation of hippocampal brain-derived neurotrophic factors and prefrontal cortex 5-hydroxytryptamine levels. The inactivated thallus provided by the invention is high in stability, good in safety and suitable for developing related drugs.

Described herein are methods and compositions for treating cancer and for predicting a subjects' response to combination checkpoint inhibitor therapy. Aspects of the disclosure relate to a method of treating cancer and / or reducing toxicity to a therapy in a subject comprising administering to the subject a composition comprising at least one isolated or purified population of bacteria belonging to one or more of the genera Flavonifractor, Dielma, Akkermansia, Alistipes, Bacteroides, Butyricimonas, Vampirovibrio, Tyzzerella, Parabacteroides distasonis, Fournierella, Fournierella massiliensis, Eisenbergiella tayi, Tissierellales, Hungateiclostridium thermocellum, Dorea formicigenerans, Caloramator coolhaasi, Muricomes, Geosporobacter, Prevotella paludivivens, Lactobacillus secaliphilus, Bacteroides finegoldii, Lactobacillus johnsonii, Parapedobacter composti, and Anaerotignum lactatifermentans and wherein the method further comprises treating the subject with a combination of (i) a PD-1, PDL1, or PDL2 inhibitor and (ii) a CTLA-4, B7-1, CN or B7-2 inhibitor.

This invention discloses the application of *Lactobacillus johnsonii* cell-free supernatant in inhibiting *Salmonella* biofilms, belonging to the field of microbial technology. This invention provides a novel use for *Lactobacillus johnsonii* BNCC186110 cell-free supernatant, which can inhibit the formation of *Salmonella typhimurium* SL1344 and 14028 biofilms, disrupt *Salmonella typhimurium* SL1344 and 14028 biofilms, thereby reducing the colonization of *Salmonella typhimurium* SL1344 and 14028.

The invention discloses human-derived lactobacillus johnsonii HA1108 and application thereof in preparation of biological agents and / or medicines for treating or relieving Parkinson's disease, and belongs to the technical field of biological medicines. The invention provides a strain of lactobacillus johnsonii, which is classified and named as Lactobacillus johnsonii, and the preservation number of the lactobacillus johnsonii is CGMCC (China General Microbiological Culture Collection Center) No.35865. Based on'flora-intestine-brain axis', the lactobacillus johnsonii HA1108 can improve dyskinesia in Parkinson's disease, relieve deletion of dopaminergic neurons of nigra in the brain, increase protein expression of tyrosine hydroxylase at the nigra part in the brain, and improve the immunity of the Parkinson's disease. The microbial inoculum prepared from the lactobacillus johnsonii HA1108 does not affect the body weight after being eaten for a long time, and a new choice is provided for patients with Parkinson's disease. The screened lactobacillus johnsonii HA1108 has important significance in preparation of biological agents or medicines for treating or relieving Parkinson's disease, improving dyskinesia and improving tyrosine hydroxylase expression, has safety and application value, and is wide in market prospect.

The invention belongs to the technical field of microorganisms, and particularly relates to a preparation method and application of a lactobacillus johnsonii ZJUIDS09 metagen capable of improving human immunity. The invention discloses a preparation method of a lactobacillus johnsonii ZJUIDS09 metagen capable of improving immunity. The lactobacillus johnsonii ZJUIDS09 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) NO.22608 is used for preparing the lactobacillus johnsonii ZJUIDS09 metagen. The invention also provides an application of the lactobacillus johnsonii ZJUIDS09 metagen prepared by the method in preparation of a product for improving immunity at the same time.

The invention discloses lactobacillus johnsonii for preventing and treating pullorum disease salmonellosis and application of the lactobacillus johnsonii, and belongs to the field of microorganisms. According to the invention, a strain of Lactobacillus johnsonii LMZ8 is separated and screened, and the preservation number of the strain of Lactobacillus johnsonii LMZ8 is GDMCC No: 66614. The lactobacillus johnsonii LMZ8 is good in acid resistance and has certain tolerance to high-concentration cholate. Experimental results show that the lactobacillus johnsonii LMZ8 can effectively inhibit the growth of various pathogenic bacteria such as salmonella typhimurium and salmonella enteritidis, especially has a prominent inhibition effect on five strains of multi-drug-resistant salmonella pullorum with no same drug resistance spectrum, can effectively prevent and treat the pullorum disease caused by salmonella pullorum, and improves the growth performance of chicks. The lactobacillus johnsonii LMZ8 shows remarkable development potential in the aspects of preventing and controlling food-borne pathogenic bacteria and preventing and treating diseases such as pullorum disease, and has a wide development prospect.

The application discloses an anti-inflammatory soothing traditional Chinese medicine composition ferment and a preparation method and application thereof, and relates to the field of cosmetics. The traditional Chinese medicine composition ferment is obtained by fermenting traditional Chinese medicine composition forsythia, phellodendron, honeysuckle and dandelion by lactobacillus johnsonii with strain number CICC 6252, significantly improves the content of total flavonoids, chlorogenic acid, berberine and forsythia liposide in the traditional Chinese medicine composition, and obviously enhances the effects of antioxidation, antibiosis, anti-inflammation and soothing, and has a wide application prospect in the fields of cosmetics and medicine. The application also adjusts the mass ratio of the traditional Chinese medicine composition ferment, glycyrrhizic acid dipotassium and allantoin to (3.0-7.0):0.2:0.2, and obtains a composition for anti-inflammation and soothing, and the three components synergistically act to enhance the anti-inflammatory effect.

The invention relates to the technical field of microorganisms, in particular to lactobacillus johnsonii D8, application thereof and a probiotic agent. The lactobacillus johnsonii D8 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on August 14, 2025, and the preservation number is CGMCC No.35619. The lactobacillus johnsonii D8 is a lactobacillus johnsonii strain. The lactobacillus johnsonii D8 provided by the invention can reduce the death rate of salmonella to the domestic pigeons after being drenched into the domestic pigeons, obviously alleviates the spleen index reduction and the immune globulin IgA reduction in serum caused by the salmonella, reduces the abundance of pathogenic bacteria in intestinal flora, and has a good probiotic effect on the domestic pigeons.

The invention discloses a lactobacillus johnsonii YS my4 strain with a cryptosporidium infection resisting effect and application of the lactobacillus johnsonii YS my4 strain. The preservation number of the YS my4 strain is CCTCC (China Center For Type Culture Collection) M 20253011. The strain disclosed by the invention has the characteristics of cholate resistance, intestinal juice resistance, strong adhesiveness and capability of inhibiting salmonella and staphylococcus aureus. In addition, the strain has no hemolytic rings, and the strain has no influence on body indexes and can increase the body weight after gavage of suckling rats, so that the strain is proved to be high in safety and can be applied to the fields of medicine and food. According to the invention, the YS my4 strain is intragastrically fed to a pseudo-sterile suckling mouse infected by cryptosporidium parvum, and it is found that the strain can activate immune defense of the intestinal tract of a host by improving the MAPK phosphorylation level of the host in the state of cryptosporidium parvum infection, so that the insect loading amount of the cryptosporidium parvum is remarkably reduced; meanwhile, the YS my4 strain can improve the expression level of tight junction proteins Occludin and CLDN4, relieve pathological damage of ileum tissues and improve the intestinal barrier function, and has important application value in prevention and treatment of cryptosporidium parvum infection.

The invention discloses an application of lactobacillus johnsonii in promoting in-vitro maturation of porcine oocytes, and a synergistic regulation system is constructed by optimizing formulas of an oocyte maturation culture solution, an electric activation solution and an embryo culture solution. The application can effectively promote the in-vitro maturation rate of the porcine oocytes to be increased from 68.84% to 77.60%, promote the discharge of first polar bodies, reduce the apoptosis rate of the oocytes and improve the development potential of the oocytes after nuclear transplantation. Therefore, the in-vitro maturation efficiency of the oocytes is improved, the problems of low maturation efficiency, high apoptosis ratio and long culture period at present are solved, and the technical system can provide more high-quality oocytes for somatic cell nuclear transplantation, manual cloning, in-vitro fertilization, transgenic cloning, gene editing and the like, and has a wide application prospect in actual production.

The present invention relates to a complex Lactobacilluscomposition for alleviating atopic dermatitis. The complex Lactobacilluscomposition includes at least one of Lactobacillus johnsoniiGKJ2 and L. plantarumGKK1. The complex Lactobacilluscomposition can be administered to a healthy subject in a continuation period, for significantly regulating Th1, Th2, Treg and Th17 cell immunity, altering gut microbiota, increasing the concentration of short-chain fatty acids in guts, thereby alleviating atopic dermatitis. Therefore, the complex Lactobacilluscomposition can be as an active ingredient for use in preparation of various compositions for alleviating atopic dermatitis.

This invention provides a composition containing lactic acid bacteria and its use in lowering dihydrotestosterone and improving hyperandrogenemia. The composition can lower dihydrotestosterone and improve androgenemia. The lactic acid bacteria comprise *Lactobacillus helveticus* GKS3, *Lactobacillus brevis* GKL9, *Lactobacillus johnsonii* GKJ2, *Pediococcus acidilactici* GKA4, or a combination thereof.

The invention relates to the field of microorganisms, in particular to application of lactobacillus johnsonii to preparation of a medicine for treating depression. According to the application of the lactobacillus johnsonii in preparing the medicine for treating the depression, the lactobacillus johnsonii can be used as an auxiliary medicine for treating the depression, and experiments of building a depression mouse model and feeding the lactobacillus johnsonii in groups prove that the lactobacillus johnsonii can relieve depression-like behaviors of depression mice, and the lactobacillus johnsonii can be used for treating the depression. The compound can improve hippocampal neuron injury of depression mice and can be used as a medicine for treating depression.

The present application relates to a kind of lactobacillus johnsonii and application, belong to microbial technology field.Lactobacillus johnsonii JoA9-1 of the present application is preserved in China typical culture preservation center, and the preservation number is CCTCCM2025369.Lactobacillus johnsonii JoA9-1 of the present application has no virulence factor, does not hemolyze, and has good safety, and its beneficial effect is: can produce multiple organic acids and has tolerance to acidic environment, can adapt and maintain the acidic environment of female genital tract;Can inhibit the propagation of pathogenic bacteria;Can inhibit the formation of Candida albicans hypha;It has immune regulation function, and the inhibitory effect on inflammatory factor TNF alpha is superior to clotrimazole treatment, can significantly enhance mouse vaginitis treatment;Treatment occurs in the site of vagina infection, can repair the local tissue of Candida albicans vaginitis mouse;Regulate the relative abundance of vaginal microbial flora after Candida albicans vaginitis infection of mouse, restore vaginal microbial flora environment.

The invention relates to the field of microorganisms, in particular to application of lactobacillus johnsonii in preparation of drugs for resisting drug-induced liver injury. According to the present invention, the Lactobacillus johnsonii is adopted as the auxiliary drug for relieving the drug-induced liver injury, such that the liver function and the anti-oxidation index of the drug-induced liver injury can be improved, the intestinal flora distribution can be adjusted, and the liver injury related diseases can be effectively relieved.